<DOC>
	<DOCNO>NCT00748189</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ofatumumab add chlorambucil patient untreated Chronic Lymphocytic Leukemia .</brief_summary>
	<brief_title>Ofatumumab + Chlorambucil v Chlorambucil Monotherapy Previously Untreated Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Chlorambucil , currently approve treatment frontline chronic lymphocytic leukemia , especially , limited ail elderly patient population . Several aggressive treatment option available ( e.g . fludarabine ) , however suitable CLL patient , especially ail elderly , due great toxicity . Ofatumumab effective low toxicity . The addition ofatumumab chlorambucil offer potentially effective therapy , limited toxicity . The objective study evaluate progression-free survival ( PFS ) , overall response overall survival subject previously untreated CLL ofatumumab add chlorambucil versus chlorambucil .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>confirm CLL diagnosis active CLL require treatment consider inappropriate fludarabinebased therapy treat CLL fully active minimum fully capable selfcare 50 % waking hour age 18yrs older sign write informed consent prior CLL therapy abnormal/inadequate blood value , liver , kidney function certain heart problem , active chronic infection , serious significant disease , AIHA require treatment , current cancer within last 5 year CLL transformation CLL central nervous system involvement current participation clinical study inability comply protocol activity lactate pregnant woman female patient childbearing potential ( male patient partner ) willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Untreated</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL ) , untreated</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Oncology</keyword>
</DOC>